Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $16.57

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.57.

A number of research firms have weighed in on OCUL. Scotiabank initiated coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Ocular Therapeutix in a report on Wednesday, October 16th. Finally, Robert W. Baird cut their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th.

Ocular Therapeutix Trading Down 1.2 %

NASDAQ OCUL opened at $10.27 on Friday. Ocular Therapeutix has a twelve month low of $2.00 and a twelve month high of $11.77. The business’s fifty day moving average is $9.54 and its 200 day moving average is $7.68. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -7.61 and a beta of 1.26.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The business had revenue of $16.40 million during the quarter, compared to the consensus estimate of $15.85 million. During the same quarter last year, the business earned ($0.27) EPS. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. As a group, sell-side analysts expect that Ocular Therapeutix will post -1.02 EPS for the current fiscal year.

Institutional Trading of Ocular Therapeutix

Institutional investors and hedge funds have recently modified their holdings of the business. Capital Performance Advisors LLP bought a new position in Ocular Therapeutix in the 3rd quarter valued at $70,000. Rosalind Advisors Inc. boosted its holdings in shares of Ocular Therapeutix by 18.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company’s stock worth $7,700,000 after buying an additional 135,000 shares during the last quarter. Deltec Asset Management LLC grew its position in Ocular Therapeutix by 0.4% during the third quarter. Deltec Asset Management LLC now owns 2,600,073 shares of the biopharmaceutical company’s stock valued at $22,621,000 after buying an additional 9,808 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Ocular Therapeutix by 64.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 29,989 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 11,793 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 1,015 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.